Clinical Profile of Retinal Vein Occlusion in Hospital Universiti Sains Malaysia – 7 Years Review

Authors

  • Khairul-Anwar Ibrahim Department of Ophthalmology, School of Medical Sciences, Health Campus, Universiti Sains Malaysia, 16150 Kubang Kerian, Kelantan Department of Ophthalmology, Kuliyyah of Medicine, International Islamic University Malaysia, Kuantan Campus, Bandar Indera Mahkota, 25200 Kuantan, Pahang
  • Abdul-Hadi Rosli Department of Ophthalmology, School of Medical Sciences, Health Campus, Universiti Sains Malaysia, 16150 Kubang Kerian, Kelantan Department of Ophthalmology, Kuliyyah of Medicine, International Islamic University Malaysia, Kuantan Campus, Bandar Indera Mahkota, 25200 Kuantan, Pahang
  • Mutasim Hassan Department of Ophthalmology, School of Medical Sciences, Health Campus, Universiti Sains Malaysia, 16150 Kubang Kerian, Kelantan Department of Ophthalmology, Faculty of Medicine, Al Neelain University, 11111 , PO Box 84, Khartoum, Sudan
  • Zunaina Embong Department of Ophthalmology, School of Medical Sciences, Health Campus, Universiti Sains Malaysia, 16150 Kubang Kerian, Kelantan

Keywords:

Retinal vein occlusion, macular oedema, fundus fluorescein angiography.

Abstract

To review the clinical profile of retinal vein occlusion (RVO) in Hospital Universiti Sains Malaysia (USM) from 2011 until 2017. This was a retrospective single-centre case series. The medical records of the patients presented to Ophthalmology Clinic with RVO from 2011 to 2017 were reviewed. A total of 24 patients (26 eyes) with a diagnosis of RVO in Hospital USM were reviewed. There was 91.6% of our patients were aged more than 45 years old with predominantly affected male gender (58.3%). Majority of the patients were Malays (87.5%). Hypertension (70.8%), hyperlipidemia (70.8%) and diabetes mellitus (54.2%) were the common systemic comorbidities in RVO patients. Majority of the patients (87.5%) were non-smoker. Based on type of RVO, there were 38.5% central RVO, 26.9% branch RVO, 19.2% macular branch RVO, and 15.4% hemivein occlusion. RVO was bilateral in 2 patients (8.4%). Based on fundus fluorescein angiography, 3 patients (11.5%) showed ischaemic features. Reduce vision (91.6%) was the main presenting symptoms of RVO while intraretinal haemorrhage (100%) and macular oedema (96.2%) were the most common ocular signs found in RVO. There were 16 eyes (61.5%) have visual acuity equal or better than 6/60 at presentation. Patient who had visual acuity equal or better than 6/60 showed promising improvement in visual acuity post treatment. Elderly with multiple comorbidities complaining of worsening of vision should have high index suspicion of RVO. Presenting visual acuity is associated with final visual outcome post treatment

References

Klein R, Barbar EK, Moss SE, Meuer SM, Klein BEK. The 15-year cumulative incidence of retinal vein occlusion: The Beaver Dam Eye Study. Arch Ophthalmol. 2008; 126(4): 513-518. Doi: 10.1001/archopht.126.4.513.

Mitchell P, Smith W, Chang A. Prevalence and associations of retinal vein occlusion in Australia: The Blue Mountains Eye Study. Arch. Ophthalmol. 1996; 114 (10): 1243–1247. Doi: 10.1001/archopht.1996.01100140443012.

Garcia-Arumi J, Gómez-Ulla F, Amparo N, Cervera E, Fonollosa A. Efficacy and safety of an aflibercept treat-and-extend regimen in treatment-naïve patients with macular oedema secondary to central retinal vein occlusion (CRVO): A prospective 12-month, single-arm, multicentre trial. J Ophthalmol. 2018; 8310350. Doi: 10.1155/2018/8310350.

Lim LL, Cheung N, Wang JJ, Islam FM, Mitchell P, Saw SM, et al. Prevalence and risk factors of retinal vein occlusion in an Asian population. Br J Ophthalmol. 2008; 92(10): 1316-1319. Doi: 10.1136/bjo.2008.140640.

Yasuda M, Kiyohara Y, Arakawa S, Hata Y, Yonemoto K, Doi Y, et al. Prevalence and systemic risk factors for retinal vein occlusion in a general Japanese population: The Hisayama Study. Invest Ophthalmo Vis Sci. 2010; 51(6): 3205-3209. Doi: 10.1167/iovs.09-4453.

Rehak J, Rehak M. Branch retinal vein occlusion: Pathogenesis, visual prognosis, and treatment modalities. Curr Eye Res. 2008; 33 (2): 111-131. Doi: 10.1080/02713680701851902.

Shroff D, Kothari A, Bhatia G, Gupta C. Clinical Diagnosis of retinal vein occlusion. Int J Ophthalmic Res. 2016; 2(2): 137-142.

Hayreh SS, Zimmerman MB. Branch retinal vein occlusion: Natural history of visual outcome. JAMA Ophthalmol. 2014; 132 (1): 13-22. Doi: 10.1001/jamaophthalmol.2013.5515.

The Eye Disease Case-Control Study Group. Risk factors for central retinal vein occlusion. Arch Ophthalmol. 1996; 114: 545–554.

Wang M, Khurana RN, Sadda SR. Central retinal vein occlusion in Wegener’s granulomatosis without retinal vasculitis. Br J Ophthalmol. 2006; 90(11): 1435-1436. Doi: 10.1136/bjo.2006.095703.

Sinawat S, Bunyavee C, Ratanapakorn T, Sinawat S, Laovirojjanakul W, Yospaiboon Y. Systemic abnormalities associated with retinal vein occlusion in young patients. Clin Ophthalmol. 2017; 11: 441-447. Doi: 10.2147/OPTH.S128341. Ecollection 2017.

Retinal Vein Occlusion RVO Guidelines. Royal College of Ophthalmologists 2015.

Ko J, Kwon OW, Byeon SH. Optical coherence tomography predicts visual outcome in acute central retinal vein occlusion. Retina. 2014; 34: 1132-1141.

Channa R, Smith M, Campochiaro PA. Treatment of macular edema due to retinal vein occlusions. Clin Ophthalmol. 2011; 5: 705-713.

Kida T. Mystery of retinal vein occlusion: Vasoactivity of the vein and possible involvement of endothelin-1. Biomed Res Int. 2017; 1–16. Https://doi.org/10.1155/2017/4816527.

Chen YY, Sheu SJ, Hu HY, Chu D, Chou P. Association between retinal vein occlusion and an increased risk of acute myocardial infarction: A Nationwide Population-based Follow-up Study. Plos ONE. 2017; 12(9: e0184016.

Chen YY, Yen YF, Lin JX, Feng SC, Wei LC, Lai YJ, et al. Risk of ischemic stroke, hemorrhagic stroke, and all-cause mortality in retinal vein occlusion: A Nationwide Population-Based Cohort Study. J Ophthalmol. 2018; 8629429.

Liu W, Xu L, Jonas JB. Vein occlusion in Chinese subjects. Ophthalmology. 2007; 114(9): 1795-1796.

Koh V, Cheung CY, Li X, Tian D, Wang JJ, Mitchell P, et al. Retinal vein occlusion in a multi-ethnic Asian population: The Singapore Epidemiology of Eye Disease Study. Ophthalmic Epidemiol. 2016; 23(1): 6-13. Doi: 10.3109/09286586.2015.1082604.

Shin YU, Cho H, Kim JM, Bae K, Kang MH, Shin JP, et al. Prevalence and associated factors of retinal vein occlusion in the Korean National Health and Nutritional Examination Survey, 2008–2012: A cross-sectional observational study. Medicine (Baltimore). 2016; 95(44). E5185.

O’Mahoney PR, Wong DT, Ray JG. Retinal vein occlusion and traditional risk factors for atherosclerosis. Arch Ophthalmol. 2008; 126: 692–699.

Teoh SL, Amarjeet K. A comparative study of branch retinal vein occlusion and central vein occlusion amongst Malaysian patients. Med J Malaysia. 1993; 48(4): 410-415.

Campochiaro PA, Heier JS, Feiner L, Gray S, Saroj N, Rundle AC, et al. Ranibizumab for macular edema following branch retinal vein occlusion: Six-month primary end point results of a phase III study. Ophthalmology. 2010; 117(6): 1102-1112.e1.

Brown DM, Campochiaro PA, Singh RP, Li Z, Gray S, Saroj N, et al. Ranibizumab for macular edema following central retinal vein occlusion: Six-month primary end point results of a phase III study. Ophthalmology. 2010; 117: 1124–1133.e1.

Hoerauf H, Feltgen N, Weiss C, Paulus EM, Schmitz-Valckenberg S, Pielen A, et al. Clinical efficacy and safety of ranibizumab versus dexamethasone for central retinal vein occlusion (COMRADE C): A European Label Study. Am J Ophthalmol. 2016; 169: 258-267.

Schmidt-Erfurth U, Garcia-Arumi J, Gerendas BS, Midena E, Sivaprasad S, Tadayoni R, et al. Guidelines for the management of retinal vein occlusion by the European Society of Retina Specialists (EURETINA). Ophthalmologica. 2019; 242(3): 123–162.

Hayreh SS. Retinal vein occlusion. Indian J Ophthalmol. 1994; 42: 109-132.

Noma H, Shimizu H, Mimura. Unilateral Macular Edema With Central Retinal Vein Occlusion In Systemic Lupus Erythematosus: A Case Report. Clin Ophthalmol. 2013; 7: 865–867.

Calugaru D, Calugaru M. Central Retinal Vein Occlusion In A Young Adult Case Report. Rom J Ophthalmol. 2016; 60(2): 120–124.

Azhan A, Mutasim H, Abdul-Hadi R, Khairul-Anwar I, Zunaina E. Macular branch retinal vein occlusion: A revisit and case report. J of Biomed & Clin Sci. 2018; 3(2); 18-21.

Downloads

Published

2020-12-16

Issue

Vol. 5 No. 2 (2020): December 2020

Section

Journal of Biomedical and Clinical Sciences

License

JBCS Publication Ethics

JBCS is committed to ensure the publication process follows specific academic ethics. Hence, Authors, Reviewers and Editors are required to conform to standards of ethical guidelines.

Authors
Authors should discuss objectively the significance of research work, technical detail and relevant references to enable others to replicate the experiments. JBCS do not accept fraudulent or inaccurate statements that may constitute towards unethical conduct.

Authors should ensure the originality of their works. In cases where the work and/or words of others have been used, appropriate acknowledgements should be made. JBCS do not accept plagiarism in all forms that constitute towards unethical publishing of an article.

This includes simultaneous submission of the same manuscript to more than one journal. Corresponding author is responsible for the full consensus of all co-authors in approving the final version of the paper and its submission for publication.

Reviewers
Reviewers of JBCS treat manuscripts received for review as confidential documents. Therefore, Reviewers must ensure the confidentiality and should not use privileged information and/or ideas obtained through peer review for personal advantage.

Reviews should be conducted based on academic merit and observations should be formulated clearly with supporting arguments. In cases where selected Reviewer feels unqualified to review a manuscript, Reviewer should notify the editor and excuse himself from the review process in TWO (2) weeks time from the review offer is made.

In any reasonable circumstances, Reviewers should not consider to evaluate manuscripts if they have conflicts of interest (i.e: competitive, collaborative and/or other connections with any of the authors, companies, or institutions affiliated to the papers).

Editors
Editors should evaluate manuscripts exclusively based on their academic merit. JBCS strictly do not allow editors to use unpublished information of authors  without the written consent of the author. Editors are required to take appropriate responsive actions if ethical complaints have been presented concerning a submitted manuscript or published paper.

CONFLICT OF INTEREST

Journal of Biomedical and Clinical Sciences requires authors to declare all competing interests in relation to their work. All submitted manuscripts must include a ‘competing interests section at the end of the manuscript listing all competing interests (financial and non-financial). Where authors have no competing interests, the statement should read ,The authors have declared that no competing interests exist. Editors may ask for further information relating to competing interests.

Editors and reviewers are also required to declare any competing interests and will be excluded from the peer review process if a competing interest exists. Competing interests may be financial or non-financial. A competing interest exists when the authors interpretation of data or presentation of information may be influenced by their personal or financial relationship with other people or organizations. Authors should disclose any financial competing interests but also any non-financial competing interests that may cause them embarrassment if they were to become public after the publication of the article.

HUMAN AND ANIMAL RIGHTS

All research must have been carried out within an appropriate ethical framework. If there is suspicion that work has not taken place within an appropriate ethical framework, Editors will follow the Misconduct policy and may reject the manuscript, and/or contact the author(s) institution or ethics committee. On rare occasions, if the Editor has serious concerns about the ethics of a study, the manuscript may be rejected on ethical grounds, even if approval from an ethics committee has been obtained.

Research involving human subjects, human material, or human data, must have been performed in accordance with the Declaration of Helsinki and must have been approved by an appropriate ethics committee. A statement detailing this, including the name of the ethics committee and the reference number where appropriate, must appear in all manuscripts reporting such research. Further information and documentation to support this should be made available to Editors on request.

Experimental research on vertebrates or any regulated invertebrates must comply with institutional, national, or international guidelines, and where available should have been approved by an appropriate ethics committee. The Basel Declaration outlines fundamental principles to adhere to when conducting research in animals and the International Council for Laboratory Animal Science (ICLAS) has also published ethical guidelines.

A statement detailing compliance with relevant guidelines (e.g. the revised Animals (Scientific Procedures) Act 1986 in the UK and Directive 2010/63/EU in Europe) and/or ethical approval (including the name of the ethics committee and the reference number where appropriate) must be included in the manuscript. The Editor will take account of animal welfare issues and reserves the right to reject a manuscript, especially if the research involves protocols that are inconsistent with commonly accepted norms of animal research. In rare cases, Editors may contact the ethics committee for further information.

INFORMED CONSENT

For all research involving human subjects, informed consent to participate in the study should be obtained from participants (or their parent or guardian in the case of children under 16) and a statement to this effect should appear in the manuscript, this includes to all manuscripts that include details, images, or videos relating to individual participants.

DATA SHARING POLICY

JBCS strongly encourages that all datasets on which the conclusions of the paper rely should be available to readers. We encourage authors to ensure that their datasets are either deposited in publicly available repositories (where available and appropriate) or presented in the main manuscript or additional supporting files, in machine-readable format (such as spreadsheets rather than PDFs) whenever possible

Authors who do not wish to share their data must state that data will not be shared, and give the reason.

COPYRIGHT NOTICE

The JBCS retains the copyright of published manuscripts under the terms of the Copyright Transfer Agreement. However, the journal permits unrestricted use, distribution, and reproduction in any medium, provided permission to reuse, distribute and reproduce is obtained from the Journal's Editor and the original work is properly cited.

While the advice and information in this journal are believed to be true and accurate on the date of its going to press, neither the authors, the editors, nor the publisher can accept any legal responsibility for any errors or omissions that may be made. The publisher makes no warranty, express or implied, with respect to the material contained herein.

Copyright (c) 2023 Journal of Biomedical and Clinical Sciences (JBCS)

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.